Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents

被引：43

作者：

Baldo, Vincenzo ^{[1
]}

Baldovin, Tatjana ^{[1
]}

Pellegrini, Michele ^{[2
]}

Angiolelli, Gabriele ^{[3
]}

Majori, Silvia ^{[4
]}

Floreani, Annarosa ^{[5
]}

Busana, Marta Cecilia ^{[1
]}

Bertoncello, Chiara ^{[1
]}

Trivello, Renzo ^{[1
]}

机构：

[1] Univ Padua, Inst Hyg, Dept Environm Med & Publ Hlth, I-35151 Padua, Italy

[2] Novartis Vaccines & Diagnost SRL, Global Clin Res & Dev, I-53100 Siena, Italy

[3] Veneto Reg, Local Hlth Unit 13, I-30035 Mirano, Italy

[4] Univ Verona, Dept Med & Publ Hlth, Sect Hyg & Prevent Environm & Occupat Med, I-37134 Verona, Italy

[5] Univ Padua, Dept Surg & Gastroenterol Sci, I-35100 Padua, Italy

来源：

CLINICAL & DEVELOPMENTAL IMMUNOLOGY | 2010年

关键词：

IMMUNE-RESPONSES; T-CELLS; VIRUS; ANTIBODY; MORTALITY; OLDER; HOSPITALIZATIONS; EPIDEMIOLOGY; PROTECTION; INCREASE;

D O I：

10.1155/2010/517198

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We studied whether MF59-adjuvanted influenza vaccine improves immunity against drifted influenza strains in institutionalised elderly with underling chronic health conditions. Sera from a randomized study, comparing MF59-adjuvanted (Sub/MF59, n = 72), virosomal (SVV, n = 39), and split (n = 88) vaccines, were retested using a hemagglutination inhibition (HI) assay against homologous (Northern Hemisphere [NH] 1998/99) and drifted (NH 2006/07) strains. Corrected postvaccination HI antibody titres were significantly higher with Sub/MF59 than SVV for all strains; GMTs against homologous A/H3N2 and B and both drifted A strains were significantly higher for Sub/MF59 than split. Seroprotection rates and mean-fold titer increases were generally higher with Sub/MF59 for all A influenza strains. MF59-adjuvanted influenza vaccine induced greater and broader immune responses in elderly people with chronic conditions, than conventional virosomal and split vaccines, particularly for A/H1 and A/H3 strains, potentially giving clinical benefit in seasons where antigenic mismatch occurs.

引用

页数：8

共 33 条

[1] Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses [J].

Ansaldi, F ;

Bacilieri, S ;

Banfi, F ;

Durando, P ;

Sticchi, L ;

Icardi, G ;

Gasparini, R .

CLINICAL AND VACCINE IMMUNOLOGY, 2006, 13 (01) :162-164

[2] Cross-protection by MF59™-adjuvanted influenza vaccine:: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses [J].

Ansaldi, Filippo ;

Bacilieri, Sabrina ;

Durando, Paolo ;

Sticchi, Laura ;

Valle, Laura ;

Montomoli, Ernanuele ;

Icardi, Giancarlo ;

Gasparini, Roberto ;

Crovari, Pietro .

VACCINE, 2008, 26 (12) :1525-1529

[3] Comparison of three different influenza vaccines in institutionalised elderly [J].

Baldo, V ;

Menegon, T ;

Bonello, C ;

Floreani, A ;

Trivello, R .

VACCINE, 2001, 19 (25-26) :3472-3475

[4] Seroprotection rate, mean fold increase, seroconversion rate:: which parameter adequately expresses seroresponse to influenza vaccination? [J].

Beyer, WEP ;

Palache, AM ;

Lüchters, G ;

Nauta, J ;

Osterhaus, ADME .

VIRUS RESEARCH, 2004, 103 (1-2) :125-132

[5] CLINICAL MANIFESTATIONS AND CONSEQUENCES OF INFLUENZA [J].

CATE, TR .

AMERICAN JOURNAL OF MEDICINE, 1987, 82 (6A) :15-19

[6]

CLEMENTS ML, 1997, NEW GENERATION VACCI, P545

[7] Global epidemiology of influenza: Past and present [J].

Cox, NJ ;

Subbarao, K .

ANNUAL REVIEW OF MEDICINE, 2000, 51 :407-421

[8]

de Jong JC, 2000, J MED VIROL, V61, P94, DOI 10.1002/(SICI)1096-9071(200005)61:1<94::AID-JMV15>3.0.CO

[9]

2-C

[10] An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine [J].

Del Giudice, G ;

Hilbert, AK ;

Bugarini, R ;

Minutello, A ;

Popova, O ;

Toneatto, D ;

Schoendorf, I ;

Borkowski, A ;

Rappuoli, R ;

Podda, A .

VACCINE, 2006, 24 (16) :3063-3065

← 1 2 3 4 →